Roche Palo Alto LLC

Hoffmann-la Roche Inc.

Steven Swallow

James Patrick Dunn

Zachary Kevin Sweeney

Sally Redshaw

Joseph Armstrong Martin

Taraneh Mirzadegan

Eric Brian Sjogren

Gareth J Thomas

Joan Heather Hogg

Brian William Dymock

Emmanuel Demont

This invention relates to methods of treating an HIV infection with novel heterocyclic compounds of formula I wherein R&#x2014;R, Xand Xare as defined in the summary and pharmaceutically acceptable salts, and methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I. 

Nonnucleoside reverse transcriptase inhibitors

This invention relates to novel pyrazole derivatives of formula I wherein R1 to R4 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I and pharmaceutical compositions containing of formula I admixed with at least one solvent, carrier or excipient. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated 

This invention relates to novel heterocyclic compounds of formula I wherein R&#x2014;R, Xand Xare as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I, pharmaceutical compositions containing of formula I admixed with at least one solvent, carrier or excipient and processes to prepare compounds of formula I. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated 

Non-nucleoside reverse transcriptase inhibitors

This invention relates to novel pyridazinone derivatives of formula I wherein R&#x2013;R, R, Rand Xare as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I, pharmaceutical compositions containing of formula I admixed with at least one solvent, carrier or excipient and processes to prepare compounds of formula I. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated 

Carbocyclic HIV protease inhibitors

The present invention discloses novel isoquinoline carboxamide derivatives which are HIV protease inhibitors or prodrugs thereof, a process for their manufacture, pharmaceutical compositions and the use of such compounds in medicine. In particular, the compounds are hydroxyethylamine tripeptide mimetics which act as inhibitors of the HIV aspartyl protease, an essential enzyme in the replicative life cycle of HIV. Consequently, the compounds of this invention may be advantageously used in the treatment of HIV infection, either alone or in combination with other inhibitors of HIV viral replication or with pharmacoenhancers such as cytochrome P450 inhibitors.

Growing community of inventors

Los Altos, CA, United States of America

Steven Swallow